Company retains entrepreneur and philanthropist to contribute to the launch of neuropacs’ innovative software for the diagnostic of Parkinson’s Disease.
GAINESVILLE, FL – neuropacsTM, a leading innovator in AI-driven neurological diagnostics, today announced that Mr. Rick Staab has accepted to serve on neuropacs’ Board of Directors.
Mr. Rick Staab is the former President and CEO of the InterMed Group. Mr. Staab is the chairperson for the University of Florida’s Movement Disorder Center (The Fixel Institute) and serves on the advisory councils for Santa Fe College’s Biomedical Program and Nuclear Medicine program. He has over 30 years of experience in the medical equipment servicing industry. Outside of InterMed, Rick has pursued several other entrepreneurial and philanthropic ventures. Rick serves on the Executive Board of Directors/Presidents Council/Lifetime Member for the University of Florida Foundation, BBVA Bank Board, LifeSouth Community Blood Centers Board and has served on the Executive Board for the Gainesville Chamber of Commerce and chaired the Chamber of Commerce talent alignment and education committee signing the first education compact.
Dr. Martin Handfield, neuropacs’ President and CEO, commented:” at neuropacsTM, we believe in the power of collaboration and innovation, and with Rick’s insight, vision and experience, we’re poised to take significant strides toward shaping the positioning of AI in medical imaging.” He added: “Mr. Staab’s dedication to the success of his companies and philanthropies in the Gainesville community truly exemplify unparalleled expertise and forward-thinking insights that promise to help revolutionize the future of impactful AI applications in the diagnostic of neurodegenerative disorders”.
“I’m excited with the opportunity to help commercialize neuropacs’ algorithm, and I believe that neuropacs’ novel diagnostic tool has the potential to change how several neurodegenerative diseases will soon be diagnosed, ultimately enabling earlier intervention and improved patient outcomes”, commented Mr. Staab.
For more information about neuropacsTM and its revolutionary diagnostic solutions, visit neuropacs.com.
About neuropacsTM:
neuropacsTM is a pioneering neurological technology company dedicated to developing innovative AI-driven diagnostics. With a commitment to advancing healthcare through cutting-edge technologies, neuropacsTM remains at the forefront of revolutionizing clinical care standards.
Forward-Looking Statements
This communication includes express and implied “forward-looking statements.” Forward-looking statements include all statements that are not historical facts and in some cases, can be identified by terms such as “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. By their nature, these statements are subject to numerous risks and uncertainties, that could cause actual results, performance or achievement to differ materially and adversely from those anticipated or implied in the statements. You should not rely upon forward-looking statements as predictions of future events. Although our management believes that the expectations reflected in our statements are reasonable, we cannot guarantee that the future results, performance, or events and circumstances described in the forward-looking statements will be achieved or occur. Recipients are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date such statements are made and should not be construed as statements of fact. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, any future presentations, or otherwise, except as required by applicable law.